IFNB1 and myeloid sarcoma: Interferon beta (IFN-β) and glatiramer acetate (GA), being the first two introduced drugs, are able to alter T-cell responses, are injectable, and still remain the “first line” therapies for MS, owing to their relative safety and proven efficacy.